Following the accomplishments of PD-1 and CTLA-4 blockade, TIM-3 and LAG-3 are currently being explored in various pre-clinical and clinical trials to promote effective anti-tumor immunity for clinical benefits (63). Here, HAVCR2 is linked to neoplasm.